Table 1.
Characteristics of stage IV NSCLC patients.
| All study patients (N = 894) | No irAE (N = 696) | With irAE (N = 198) | p-value | |
|---|---|---|---|---|
| Age, median; IQR | 65;12 | 65;12 | 0.57 | |
| Sex, male/female | 419/272 | 117/81 | 0.67 | |
| Never/light-smokers (<10 py) | 70/650 | 20/186 | 0.60 | |
| Pack–years, mean (SE) | 38 (1.0) | 40 (2.0) | 0.34 | |
| ECOG PS, median (IQR) | 1 (1) | 0 (1) | 0.016 | |
| PD-L1 TPS ≥1/<1%, n (%) | 489/140 | 159 (24)/22 (14) | 0.003 | |
| PD-L1 TPS, mean (SE) | 34.3 (1.5) | 42.6 (2.8) | 0.008 | |
| NLR ≥5/<5, n (%) | 444/233 | 93 (17)/98 (29) | <0.001 | |
| NLR, mean (SE) | 9.0 (0.3) | 7.0 (0.7) | 0.005 | |
| ICI-monotherapy, n (% of ICI-monotherapy) | 483 | 139 (22) | 0.75 | |
| Chemo-IO, n (% of Chemo-IO) | 213 | 58 (21) | ||
| ICI-monotherapy, 1L, n (% of first line) | 159 | 56 (26) | 0.08 | |
| ICI-monotherapy, lines 2–8, (% of later lines) | 324 | 83 (20) | ||
| CHT-IO, 1L, n (% of first line) | 198 | 53 (21) | 0.68 | |
| CHT-IO, lines 2–8, (% of later lines) | 15 | 5 (25) | ||
| ICI drug, 1L, n (% of drug) | Pembrolizumab | 118 | 48 (29) | 0.17 |
| Nivolumab | 35 | 9 (20) | ||
| Atezolizumab | 6 | 0 (0) | ||
| ICI drug, lines 2–8, n (% of drug) | Nivolumab | 213 | 54 (20) | 0.16 |
| Pembrolizumab | 62 | 20 (24) | ||
| Atezolizumab | 46 | 8 (15) | ||
| Durvalumab | 3 | 0 (0) | ||
| ICI type, across lines, n (%) | PD-1 inhibitor | 428 | 131 (23) | 0.053 |
| PD-L1 inhibitor | 55 | 8 (13) | ||
| CHT-IO, 1L, n (% of drug) | CHT + pembrolizumab | 189 | 49 (21) | 0.67 |
| CHT + atezolizumab | 4 | 2 (33) | ||
| CHT + durvalumab | 5 | 2 (29) | ||
| CHT-IO, lines 2–8, n (% of drug) | CHT + pembrolizumab | 4 | 2 (33) | 0.74 |
| CHT + atezolizumab | 9 | 2 (18) | ||
| CHT + durvalumab | 2 | 1 (33) | ||
| CHT-IO, across lines, n (%) | CHT + PD-1 inhibitor | 193 | 51 (21) | 0.55 |
| CHT + PD-1 inhibitor | 20 | 7 (26) | ||
| Any radiotherapy | 246/701 | 63/198 | 0.37 | |
| Thoracic radiotherapy (with respect to pneumonitis) | 110/860 | 6/40 | 0.68 | |
ECOG PS, ECOG performance status; ICI, immune checkpoint inhibitor; IO, immunotherapy; 1L, first line; NLR, neutrophil-to-lymphocyte ratio. All bold values of the table show a significance of p< 0.05.